42561-71-7

Basic information

• Product Name: 2-[(2E)-4-BROMOBUT-2-EN-1-YL]-1H-ISOINDOLE-1,3(2H)-DIONE
• Synonyms: 2-[(2E)-4-BROMOBUT-2-EN-1-YL]-1H-ISOINDOLE-1,3(2H)-DIONE
• CAS NO: 42561-71-7
• Molecular Formula: C₁₂H₁₀BrNO₂
• Molecular Weight: 280.1173
• Mol File: 42561-71-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 99-101 °C(Solv: methanol (67-56-1))
• Boiling Point: 389.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.556±0.06 g/cm3(Predicted)
• PKA: -2.28±0.20(Predicted)
• CAS DataBase Reference: 2-[(2E)-4-BROMOBUT-2-EN-1-YL]-1H-ISOINDOLE-1,3(2H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2E)-4-BROMOBUT-2-EN-1-YL]-1H-ISOINDOLE-1,3(2H)-DIONE(42561-71-7)
• EPA Substance Registry System: 2-[(2E)-4-BROMOBUT-2-EN-1-YL]-1H-ISOINDOLE-1,3(2H)-DIONE(42561-71-7)

Safety Data

• Hazardous Substances Data: 42561-71-7(Hazardous Substances Data)

Usage

Molecular weight

294.14 g/mol

Chemical group

Isoindole-1,3-dione with a 4-bromobut-2-en-1-yl group

Usage

Organic synthesis, pharmaceutical research, potential applications in new drug or material development

Specific properties and potential uses

Dependent on the context and specific research or application being pursued

Upstream product

• 821-06-7 (E)-1,4-dibromobutene 
• 1074-82-4 potassium phtalimide 
• 6974-12-5 1,4-dibromo-2-butene 

Downstream Products

• 223550-60-5 [4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-[(S)-2-((S)-3-methyl-1-phenylcarbamoyl-butylcarbamoyl)-4-phenyl-butyl]-phosphinic acid 

Relevant articles and documents

Heterocyclic compound and application thereof

The present disclosure relates to a heterocyclic compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, an optical isomer, a raceme, a polymorphic substance, a solvate or an isotope labeled compound thereof, a pharmaceutical composition containing the heterocyclic compound, and a pharmaceutical use thereof. The heterocyclic compound disclosed by the invention is an immunomodulator, and particularly relates to an immunomodulator of a compound for activating STING.

Design, synthesis and bioactivity of novel phthalimide derivatives as acetylcholinesterase inhibitors

A series of novel phthalimide derivatives related to benzylpiperazine were synthesized and evaluated as cholinesterase inhibitors. The results showed that all compounds were able to inhibit acetylcholinesterase (AChE), with two of them dramatically inhibiting butyrylcholinesterase (BuChE). Most compounds exhibited potent anti-AChE activity in the range of nM concentrations. In particular, compounds 7aIII and 10a showed the most potent activity with the IC50 values of 18.44 nM and 13.58 nM, respectively. To understand the excellent activity of these compounds, the structure-activity relationship was further examined. The protein-ligand docking study demonstrated that the target compounds have special binding modes and these results are in agreement with the kinetic study.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS

2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i,e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.